View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 10, 2021updated 11 Jul 2022 2:19pm

Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers

The Phase I/II clinical trial of tegavivint is fully sponsored by COG PEP-CTN, with support from Iterion.

Iterion Therapeutics has announced the start of a Phase I/II clinical trial to assess tegavivint in treating paediatric cancers.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Tegavivint is a small molecule inhibitor of the Transducin Beta-like Protein One (TBL1), which is a novel target in the Wnt/beta-catenin signalling pathway.

It binds to TBL1 to prevent nuclear beta-catenin signalling and oncogenic activity.

In the clinical trial, the inhibitor will also be investigated as a potential treatment for lymphomas, sarcomas and other solid tumours that are common in paediatric populations.

Baylor College of Medicine Haematology-Oncology Section Pediatrics Department assistant professor Sarah Whittle is leading the Phase I/II clinical trial, which has already started enrolling patients this month with recurrent or refractory solid tumours, including sarcomas and lymphomas.

Children’s Oncology Group Pediatric Early Phase Clinical Trials Network (COG PEP-CTN) is sponsoring the trial, with support from Iterion.

Iterion stated that the Phase I/II study will be conducted at 21 consortium clinical centres, which include the leading paediatric cancer centres in the US.

Iterion CEO Rahul Aras said: “We are very pleased to collaborate with COG-NCI to initiate this Phase 1/2 clinical trial of tegavivint as a potential targeted treatment for paediatric cancers.

“Research involving tegavivint suggests that it could be ideally suited to addressing a range of paediatric cancers based on its ability to inhibit TBL1 and, in turn, disrupt the oncogenic activity of beta-catenin.

“This unique mechanism of action, combined with tegavivint’s demonstrated safety profile in desmoid tumour patients, formed the basis for COG PEP-CTN to initiate the Phase I/II trial as a first step in the potential development of tegavivint for both solid and haematologic paediatric tumours.”

The company noted that the new Phase I/II study follows positive clinical data obtained from the Phase I/IIa desmoid study conducted in 24 adult subjects with progressive and nonresectable desmoid tumours.

According to the data, tegavivint was well-tolerated and dose-limiting toxicities were also not observed.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena